SpacePharma

SpacePharma is a Swiss-Israeli biotechnology and space-life-sciences company focused on conducting scientific research in microgravity. Its work is aimed primarily at pharmaceutical research and development, chemistry, biology, and related life-science applications that can benefit from an environment not readily reproducible on Earth. The company is described as the first fully private, commercially oriented enterprise established specifically to conduct pharmaceutical research and development and manufacturing in space. The company was founded by Yossi Yamin, a former commander of a satellite unit in the Israel Defense Forces. Its business model combines spacecraft, space-station payloads, miniaturized laboratory hardware, remote operations, and experimental services. Rather than relying only on conventional terrestrial laboratories, SpacePharma places compact, unmanned, remotely controlled, and automated systems in orbit. These systems use lab-on-a-chip technology to reduce the volume, mass, and operational complexity normally associated with biological and chemical experimentation. SpacePharma's platforms are designed to support a range of experiments, including crystallization, emulsion behavior, enzyme activity, antimicrobial-resistance research, and other biological or chemical studies. Microgravity can alter fluid behavior, crystal growth, sedimentation, cellular processes, and other physical or biological phenomena. Researchers can therefore use the company's orbital infrastructure to investigate conditions that are difficult or impossible to reproduce consistently in terrestrial laboratories. The company has operated both free-flying spacecraft and laboratory systems installed aboard the International Space Station. Its DIDO-2 and DIDO-3 satellites carried experiments into orbit in 2017 and 2020, respectively. SpacePharma has also sent at least seven autonomous laboratory units to the International Space Station since 2017. The early NEXUS-1 and NEXUS-2 units were followed by SPAd and SPAd-2 systems. In April 2022, a SPAd-2 laboratory reached the station through the Axiom-1 private astronaut mission and supported experiments concerning bone loss, DNA-damage repair, and the cultivation of cultured meat in space. SpacePharma's offering is best understood as an integrated research service rather than a conventional consumer-facing pharmaceutical brand. Customers and research partners can obtain access to orbital laboratory capacity, experiment design and preparation, payload integration, launch opportunities, remote operation, and the return or analysis of experimental results. The company has also announced work on MoTi, a proposed larger-scale pharmaceutical manufacturing facility in orbit. Publicly available material does not establish that MoTi is operational, nor does it provide a confirmed completion date. By the mid-2020s, SpacePharma maintained a geographically distributed presence spanning Israel, Switzerland, and the United States. Its activities place it at the intersection of biotechnology, pharmaceutical research, microgravity science, commercial spaceflight, and in-space manufacturing. The company remains an active specialist venture whose significance depends on converting orbital experimentation into useful pharmaceutical, biomedical, and manufacturing knowledge.

SpacePharma emerged as a commercial biotechnology company built around the idea that pharmaceutical and life-science research could benefit from controlled microgravity. It was founded by Yossi Yamin, a former commander of an Israeli satellite unit. The company is described as the first fully private, commercially oriented company created specifically to pursue pharmaceutical research and development and manufacturing in space. Its origins therefore combine Israel's satellite and aerospace expertise with the growing commercial-space and biotechnology sectors. The company's central technical approach is miniaturization. Its laboratories are unmanned, remotely controlled, and automated, with lab-on-a-chip architectures that allow experiments to be conducted using compact hardware. This is important for orbital research because launch mass, volume, power, crew time, and access to spacecraft are constrained. By automating the experiments and operating them remotely, SpacePharma can support research without requiring a permanent human operator at the laboratory location. SpacePharma developed two complementary operating modes. One involves free-flying satellites carrying research payloads; the other involves laboratory units installed aboard the International Space Station. The DIDO-2 satellite, launched in 2017, carried experiments involving processes such as crystallization, emulsions, enzyme activity, and antimicrobial resistance. DIDO-3 followed in 2020, extending the company's use of independent orbital platforms for microgravity experimentation. Beginning in 2017, the company also sent autonomous laboratories to the International Space Station. The initial NEXUS-1 and NEXUS-2 units were followed by SPAd and SPAd-2 systems. These payloads gave the company access to the station's sustained microgravity environment while allowing experiments to be controlled from Earth. The approach supported a series of studies in biological and chemical science and created a service model in which customers could use SpacePharma hardware and mission infrastructure without developing a complete space laboratory themselves. A notable later deployment occurred in April 2022, when a SPAd-2 laboratory was delivered to the station on Axiom-1, Axiom Space's first private astronaut mission to the International Space Station. The laboratory supported experiments examining bone loss, DNA-damage repair, and cultured-meat cultivation in space. These topics illustrate the breadth of SpacePharma's intended market: pharmaceutical discovery and formulation, human-health research, cellular and molecular biology, and future food-production technologies. As the company expanded, its activities came to include offices in Herzliya, Courgenay, and Palo Alto, together with a Space Life Sciences Lab in Exploration Park, Florida. This footprint reflects the need to connect engineering and business operations with launch, station, and US commercial-space infrastructure. SpacePharma has positioned itself as an intermediary between terrestrial research organizations and orbital experimental environments, providing hardware, payload integration, operations, and experimental access. The company has also announced MoTi, a proposed larger-scale pharmaceutical manufacturing facility in orbit. The proposal represents a shift from using space primarily as a research environment toward using it as a potential production environment. Publicly available reference material does not establish that MoTi has entered service, so it remains a forward-looking development rather than a confirmed operating facility. Overall, SpacePharma's history is defined by the progressive deployment of compact automated laboratories, the use of both satellites and the International Space Station, and an effort to turn microgravity research into a commercial biotechnology and manufacturing platform.

• 2022

  SPAd-2 delivered to the International Space Station

  [1]SpacePharmaen.wikipedia.org

  A SPAd-2 laboratory arrived aboard the Axiom-1 mission and conducted experiments related to bone loss, DNA-damage repair, and cultured meat.

• 2020

  DIDO-3 satellite launched

  [1]SpacePharmaen.wikipedia.org

  DIDO-3 continued SpacePharma's free-flying satellite research program.

• 2017

  DIDO-2 satellite launched

  [1]SpacePharmaen.wikipedia.org

  SpacePharma's DIDO-2 satellite carried experiments designed to study scientific and pharmaceutical-relevant processes in microgravity.

• 2017

  First autonomous laboratories sent to the International Space Station

  [1]SpacePharmaen.wikipedia.org

  The company began its series of station deployments with the NEXUS-1 and NEXUS-2 laboratory systems.

• MoTi orbital manufacturing concept announced

  [1]SpacePharmaen.wikipedia.org

  SpacePharma announced work on a proposed large-scale pharmaceutical manufacturing facility in orbit called MoTi.

A specialist commercial space-life-sciences provider that gives pharmaceutical, biotechnology, and research customers access to automated microgravity experimentation and prospective in-space manufacturing.

• Research satellite · 2017

  DIDO-2

  A free-flying research satellite launched in 2017 to carry experiments in microgravity. Its reported research areas included crystallization, emulsion behavior, enzyme activity, and antimicrobial resistance.

• Research satellite · 2020

  DIDO-3

  A SpacePharma satellite launched in 2020 as part of the company's free-flying orbital research program. The available reference identifies it as an experiment-bearing platform but does not provide a complete experiment list.

• International Space Station laboratory systems · 2017

  NEXUS-1 and NEXUS-2

  Early autonomous laboratory units sent to the International Space Station from 2017 onward. They formed part of SpacePharma's approach to remotely controlled, miniaturized experimentation in the station's microgravity environment.

• International Space Station laboratory systems · 2022

  SPAd and SPAd-2

  Automated orbital laboratory systems developed for SpacePharma's station-based research program. SPAd-2 was delivered to the International Space Station on Axiom-1 in April 2022 and supported studies of bone loss, DNA-damage repair, and cultured-meat cultivation.

• Proposed in-orbit pharmaceutical manufacturing facility

  MoTi

  A proposed larger-scale orbital facility intended to support pharmaceutical manufacturing in space. The available reference material describes MoTi as a development project and does not confirm that the facility is operational.

• 2022

  Deploy SPAd-2 through the Axiom-1 missionProduct launch

  Background

  The company sought to continue station-based experimentation using an autonomous laboratory designed for remote operation.

  Action taken

  SPAd-2 was delivered to the International Space Station in April 2022 on Axiom-1.

  Aftermath

  The payload supported experiments involving bone loss, DNA-damage repair, and cultured-meat cultivation.

  Source

• 2017

  Expand into both satellite and space-station laboratory operationsProduct launch

  Background

  SpacePharma pursued two orbital research architectures: free-flying satellites and autonomous laboratory payloads aboard the International Space Station.

  Action taken

  The company launched DIDO-2 and began deploying NEXUS laboratory units to the station.

  Aftermath

  This established the company's dual-platform model for commercial microgravity research.

  Source

• Develop MoTi for orbital pharmaceutical manufacturingStrategy

  Background

  SpacePharma announced an ambition to move beyond small-scale orbital experimentation toward larger-scale pharmaceutical production in space.

  Action taken

  The company announced work on a proposed in-orbit manufacturing facility named MoTi.

  Aftermath

  The available material does not establish an operating date, completed construction, or commercial production.

  Source

• 2020.06.12

  Reported2020.06.12

  InnoStudio announces international drug-development consortium[2]InnoStudio宣布成立国际药物研发联盟finanznachrichten.de

  InnoStudio announced the initiation of an international collaboration to develop a project combining microgravity research with drug research, development and formulation. The consortium is to include ComInnex, universities and space-technology companies.

Read more

1. 1SpacePharmaen.wikipedia.org
2. 2InnoStudio宣布成立国际药物研发联盟finanznachrichten.de